Based on the Eloxx Pharmaceuticals Inc stock forecast from 0 analysts, the average analyst target price for Eloxx Pharmaceuticals Inc is not available over the next 12 months. Eloxx Pharmaceuticals Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Eloxx Pharmaceuticals Inc is Bearish, which is based on 1 positive signals and 6 negative signals. At the last closing, Eloxx Pharmaceuticals Inc’s stock price was USD 0.00. Eloxx Pharmaceuticals Inc’s stock price has changed by +0.00% over the past week, 0% over the past month and -99.99% over the last year.
No recent analyst target price found for Eloxx Pharmaceuticals Inc
No recent average analyst rating found for Eloxx Pharmaceuticals Inc
Company Overview Eloxx Pharmaceuticals Inc
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts. Read Less
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial...Read More
Frequently Asked Questions About Eloxx Pharmaceuticals Inc (ELOX) Stock
Stock Target Advisor's fundamental analysis for Eloxx Pharmaceuticals Inc's stock is Bearish.
Unfortunately we do not have enough data on ELOX's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on ELOX's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on ELOX's stock to indicate if its overvalued.
The last closing price of ELOX's stock was USD 0.00.
The most recent market capitalization for ELOX is USD 314.00.
Unfortunately we do not have enough analyst data on ELOX's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Eloxx Pharmaceuticals Inc's stock.
As per our most recent records Eloxx Pharmaceuticals Inc has 18 Employees.
Eloxx Pharmaceuticals Inc's registered address is 480 Arsenal Way, Watertown, MA, United States, 02472.
You can get more information about it from Eloxx Pharmaceuticals Inc's website at https://www.eloxxpharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Eloxx Pharmaceuticals Inc (ELOX) Stock
Stock Target Advisor's fundamental analysis for Eloxx Pharmaceuticals Inc's stock is Bearish.
Unfortunately we do not have enough data on ELOX's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on ELOX's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on ELOX's stock to indicate if its overvalued.
The last closing price of ELOX's stock was USD 0.00.
The most recent market capitalization for ELOX is USD 314.00.
Unfortunately we do not have enough analyst data on ELOX's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Eloxx Pharmaceuticals Inc's stock.
As per our most recent records Eloxx Pharmaceuticals Inc has 18 Employees.
Eloxx Pharmaceuticals Inc's registered address is 480 Arsenal Way, Watertown, MA, United States, 02472.
You can get more information about it from Eloxx Pharmaceuticals Inc's website at https://www.eloxxpharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ELOX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
